DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business UpdateGlobeNewsWire • 10/31/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A. - DBVTPRNewsWire • 10/10/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of DBV Technologies S.A. - DBVTNewsfile Corp • 10/08/22
DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of DirectorsGlobeNewsWire • 10/03/22
DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 YearsGlobeNewsWire • 09/07/22
Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 08/23/22
DBV Technologies to Present at the JMP Securities Life Sciences Conference in New YorkGlobeNewsWire • 06/16/22
Has DBV Technologies (DBVT) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 06/09/22
DBV Technologies Shares Jump On Positive Data From Peanut Allergy Trial In ToddlersBenzinga • 06/08/22
DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic ToddlersGlobeNewsWire • 06/07/22
DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General MeetingGlobeNewsWire • 05/12/22